Cargando…

Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects

BACKGROUND: Lowering cholesterol levels decreases the risk of atherosclerotic diseases. Effective ways to stably reduce LDL-C level are warranted in type 2 diabetic patients, a high-risk population for CVD, with various anti-diabetic therapeutic background. The RESEARCH study focuses on LDL-C reduct...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakamoto, Kentaro, Kawamura, Mitsunobu, Watanabe, Takayuki, Ashidate, Keiko, Kohro, Takahide, Tanaka, Akira, Mori, Yasumichi, Tagami, Motoki, Hirano, Tsutomu, Yamazaki, Tsutomu, Shiba, Teruo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5483302/ https://www.ncbi.nlm.nih.gov/pubmed/28646901 http://dx.doi.org/10.1186/s12944-017-0508-4

Ejemplares similares

RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale
por: Inazawa, Takeshi, et al.
Publicado: (2013)

Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins
por: Sakamoto, Kentaro, et al.
Publicado: (2015)

Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia
por: Yamaoka-Tojo, Minako, et al.
Publicado: (2009)

Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients—REACTION 52-week study
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Influence of Municipality-Level Mean Income on Access to Aortic Valve Surgery: A Cross-Sectional Observational Study under Japan's Universal Health-Care Coverage
por: Lee, Seitetsu L., et al.
Publicado: (2014)

Body Mass Index and Sudden Cardiac Death in Japanese Patients After Acute Myocardial Infarction: Data From the JCAD Study and HIJAMI‐II Registry
por: Shiga, Tsuyoshi, et al.
Publicado: (2018)

Empagliflozin as add‐on to linagliptin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52‐week, randomized, placebo‐controlled trial
por: Kawamori, Ryuzo, et al.
Publicado: (2018)

52 Procedures in 52 Weeks: An Innovative Curriculum for Emergency Medicine Residents
por: Walsh, Ryan, et al.
Publicado: (2017)

Knowledge and Demand for Information about Islet Transplantation in Patients with Type 1 Diabetes
por: Yamamoto, Yuko, et al.
Publicado: (2011)

Fungal biotransformation of ezetimibe
por: Pervaiz, Irfan, et al.
Publicado: (2014)

Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study
por: Inagaki, Nobuya, et al.
Publicado: (2015)

Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study
por: Ishihara, Hisamitsu, et al.
Publicado: (2018)

Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY(®) compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials
por: Takeuchi, Tsutomu, et al.
Publicado: (2023)

Ezetimibe: An Unusual Suspect in Angioedema
por: Lu, Tiffany, et al.
Publicado: (2020)

Synthesis and Modeling of Ezetimibe Analogues
por: Salgado, Mateo M., et al.
Publicado: (2021)

Ezetimibe and Cancer: Is There a Connection?
por: Gu, Jia, et al.
Publicado: (2022)

A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol
por: Niedzielski, Mateusz, et al.
Publicado: (2021)

Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia
por: Joaqui, Vanessa Bedoya, et al.
Publicado: (2021)

An open-label, randomized controlled trial of sulfamethoxazole–trimethoprim for Pneumocystis prophylaxis: results of 52-week follow-up
por: Utsunomiya, Masako, et al.
Publicado: (2020)

Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia
por: Rizzo, Manfredi, et al.
Publicado: (2011)

Liver Injury Associated With Ezetimibe Monotherapy
por: Kanagalingam, Tharsan, et al.
Publicado: (2020)

Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial
por: Yamanaka, Hisashi, et al.
Publicado: (2014)

Pseudoaneurysm arising from a side branch of a graft for ascending aortic replacement
por: Suzuki, Tsutomu, et al.
Publicado: (2023)

A 52‐week multicenter randomized controlled study of the efficacy and safety of add‐on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study)
por: Yamanishi, Tomonori, et al.
Publicado: (2018)

Creative 52: weekly projects to invigorate your photography portfolio
por: Adler, Lindsay
Publicado: (2014)

DNA methylation changes in infants between 6 and 52 weeks
por: Wikenius, Ellen, et al.
Publicado: (2019)

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus
por: Onishi, Yukiko, et al.
Publicado: (2012)

T52. N-ACETYL-CYSTEINE ADD-ON TREATMENT LEADS TO AN IMPROVEMENT OF FORNIX WHITE MATTER INTEGRITY IN EARLY PSYCHOSIS
por: Klauser, Paul, et al.
Publicado: (2018)

Ezetimibe Promotes Brush Border Membrane-to-Lumen Cholesterol Efflux in the Small Intestine
por: Nakano, Takanari, et al.
Publicado: (2016)

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
por: Rosenstock, J., et al.
Publicado: (2008)

Long‐term (52‐week) efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open‐label extension of a phase III study
por: Kaku, Kohei, et al.
Publicado: (2020)

A Year with Peter Drucker - 52 Weeks of Coaching for Leadership Effectiveness
por: Maciariello, Joseph
Publicado: (2014)

Ezetimibe therapy: mechanism of action and clinical update
por: Phan, Binh An P, et al.
Publicado: (2012)

Ezetimibe: Clinical and Scientific Meaning of the IMPROVE-IT Study
por: Correia, Luis C. L.
Publicado: (2016)

Impact on urinary oxalate levels with use of ezetimibe
por: Trautman, Christopher L., et al.
Publicado: (2021)

IMPROVE-IT: A Final Closure to Carcinogenicity of Ezetimibe?
por: Lewis, Eldrin F., et al.
Publicado: (2020)

Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin
por: Farnier, Michel, et al.
Publicado: (2011)

Non–SCF-type F-box protein Roy1/Ymr258c interacts with a Rab5-like GTPase Ypt52 and inhibits Ypt52 function
por: Liu, Yuan, et al.
Publicado: (2011)

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study
por: Tanaka, Yoshiya, et al.
Publicado: (2014)

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
por: Nauck, Michael A., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_vk0qtqod2sqdc9gqbmpbkfbq93